A multicenter, open-label, phase II study of the pharmacokinetics and safety of the 100 Mcg misoprostol vaginal insert (MVI 100) in women requiring cervical ripening and induction of labor
Latest Information Update: 26 Oct 2013
At a glance
- Drugs Misoprostol (Primary)
- Indications Labour disorders; Labour induction
- Focus Pharmacokinetics
- Sponsors Ferring Pharmaceuticals
- 15 Jun 2012 Actual patient number is 0 according to ClinicalTrials.gov.
- 18 Mar 2008 The expected completion date for this trial is now 1 Dec 2008.
- 12 Mar 2008 Status changed from initiated to withdrawn prior to recruitment as reported by ClinicalTrials.gov.